The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...
Dexcom Executive Vice President and Chief Commercial Officer RIck Doubleday visited The American Journal of Managed Care® to discuss Medicare reimbursement for the Dexcom G5 and a new partnership with ...
To follow up on what it’s described as its “best year ever,” Dexcom has accelerated the development of the newest version of its mainstay continuous glucose monitor in 2021—and delivered new clinical ...
DexCom is a leading healthcare stock that has seen significant growth, with shares returning close to 1,400% in the past decade. DXCM stock has faced resistance and is currently 37% below its all-time ...
Hosted on MSN
DexCom (DXCM) Stock Is Up, What You Need To Know
Shares of medical device company DexCom (NASDAQ:DXCM) jumped 2.6% in the morning session after the company announced it would present new product features and positive clinical data at the European ...
DexCom, Inc. (NASDAQ:DXCM – Get Free Report)’s stock price gapped up prior to trading on Friday after Canaccord Genuity Group raised their price target on the stock from $103.00 to $106.00. The stock ...
Dexcom posted full-year performance that matched up closely with our estimates, and we’re leaving our fair value estimate unchanged. Reported 2021 revenue growth of 27% hit our projection on the nose.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback